Callan Family Office LLC Invests $8.55 Million in Abbott Laboratories $ABT

Callan Family Office LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 94,188 shares of the healthcare product maker's stock, valued at approximately $8,547,000.

A number of other large investors have also added to or reduced their stakes in the stock. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Up 0.1%

Shares of ABT opened at $112.63 on Monday. The firm has a fifty day moving average price of $102.61 and a 200-day moving average price of $100.14. The firm has a market capitalization of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.18 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same period in the prior year, the business earned $1.26 EPS. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories's payout ratio is presently 81.55%.

Analysts Set New Price Targets

Several research firms have weighed in on ABT. TD Cowen increased their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. Royal Bank Of Canada restated an "outperform" rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Wells Fargo & Company upped their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Finally, Piper Sandler reissued an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source